PATENT CLAIM ANALYSIS

Application Number: 16282517
Application Type: Utility
Filing Date: 2019-02
Publication Date: 2019-06
Patent Classification: ["424", "133100"]

Abstract:
Provided herein are methods of treatment and/or prevention of cancer by manipulation of commensal microflora. In particular, the amount, identity, presence, and/or ratio of microflora (e.g., gut microflora) in a subject is manipulated to facilitate one or more co-treatments.

Claim (Index 18):
The method of  claim 1 , wherein the immune checkpoint inhibitor is nivolumab, pembrolizumab, pidilizumab, AMP-224, AMP-514, STI-A1110, TSR-042, RG-7446, BMS-936559, BMS-936558, MK-3475, CT Ol l, MPDL3280A, MEDI-4736, MSB-0020718C, AUR-012 and STI-A1010.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 99.0
- Lexical Diversity: 1.2973
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15170284', '14310848', '15303985', '16041595', '15748284']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.5399283562121007
- 35 USC 102 Novelty (BERT): 0.6923850707159545
- Combined Prediction Score: 0.555174027662486
- Mean Citation Score: 355.316902
- Max Citation Score: 707.05145
- Similarity Product: 691.9072494094728

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test